The global granulocyt colony stimulating factor market is expected to grow at a CAGR of 5.5% during the forecast period, from 2021 to 2030. The growth of this market is attributed to the increasing prevalence of chronic and autoimmune disorders, which are major drivers for the growth of this market. The oncological diseases segment is expected to be the fastest-growing segment in this market during the forecast period. The global granulocyt colony stimulating factor market can be categorized into four segments: type (capsules and tablets), application (oncological diseases, blood disorders, growth hormone deficiencies, chronic and autoimmune disorders), and region (North America, Latin America, Europe, Asia Pacific and Middle East & Africa). North America accounted for a share of over 40% in 2017 owing to its high adoption rate among patients with chronic or autoimmune disorders such as rheumatoid arthritis or Crohn's disease. -Granulocyte-colony stimulating factor is a protein that stimulates the production of neutrophils, which are white blood cells that fight infection. -The global granulocyte colony stimulating factor market size was valued at USD 1.2 billion in 2016 and is expected to grow at a CAGR of 5.5% from 2017 to 2025.
Industry Growth Insights published a new data on “Granulocyte-Colony Stimulating Factor Market”. The research report is titled “Granulocyte-Colony Stimulating Factor Market research by Types (Capsules, Tablets, Others), By Applications (Oncological Diseases, Blood Disorders, Growth Hormone Deficiencies, Chronic and Autoimmune Disorders, Others), By Players/Companies BioCad, Dong-A Socio Group, Pfizer, Intas Pharmaceuticals, Novartis AG, Stada Arzneimittel, Teva Pharmaceutical Industries, Amgen, Dr. Reddy's Laboratories”.
Scope Of The Report
Report Attributes
Report Details
Report Title
Granulocyte-Colony Stimulating Factor Market Research Report
By Type
Capsules, Tablets, Others
By Application
Oncological Diseases, Blood Disorders, Growth Hormone Deficiencies, Chronic and Autoimmune Disorders, Others
By Companies
BioCad, Dong-A Socio Group, Pfizer, Intas Pharmaceuticals, Novartis AG, Stada Arzneimittel, Teva Pharmaceutical Industries, Amgen, Dr. Reddy's Laboratories
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
234
Number of Tables & Figures
164
Customization Available
Yes, the report can be customized as per your need.
Global Granulocyte-Colony Stimulating Factor Market Report Segments:
The global Granulocyte-Colony Stimulating Factor market is segmented on the basis of:
Types
Capsules, Tablets, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Oncological Diseases, Blood Disorders, Growth Hormone Deficiencies, Chronic and Autoimmune Disorders, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- BioCad
- Dong-A Socio Group
- Pfizer
- Intas Pharmaceuticals
- Novartis AG
- Stada Arzneimittel
- Teva Pharmaceutical Industries
- Amgen
- Dr. Reddy's Laboratories
Highlights of The Granulocyte-Colony Stimulating Factor Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Capsules
- Tablets
- Others
- By Application:
- Oncological Diseases
- Blood Disorders
- Growth Hormone Deficiencies
- Chronic and Autoimmune Disorders
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Granulocyte-Colony Stimulating Factor Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Granulocyte-colony stimulating factor (G-CSF) is a protein that stimulates the growth of white blood cells. G-CSF is used to treat leukemia, lymphoma, and other types of cancer.
Some of the major players in the granulocyte-colony stimulating factor market are BioCad, Dong-A Socio Group, Pfizer, Intas Pharmaceuticals, Novartis AG, Stada Arzneimittel, Teva Pharmaceutical Industries, Amgen, Dr. Reddy's Laboratories.
The granulocyte-colony stimulating factor market is expected to register a CAGR of 5.5%.
1. Executive Summary
2. Assumptions and Acronyms Used
3. Research Methodology
4. Granulocyte-Colony Stimulating Factor Market Overview
4.1. Introduction
4.1.1. Market Taxonomy
4.1.2. Market Definition
4.2. Macro-Economic Factors
4.2.1. Industry Outlook
4.3. Granulocyte-Colony Stimulating Factor Market Dynamics
4.3.1. Market Drivers
4.3.2. Market Restraints
4.3.3. Opportunity
4.3.4. Market Trends
4.4. Granulocyte-Colony Stimulating Factor Market - Supply Chain
4.5. Global Granulocyte-Colony Stimulating Factor Market Forecast
4.5.1. Granulocyte-Colony Stimulating Factor Market Size (US$ Mn) and Y-o-Y Growth
4.5.2. Granulocyte-Colony Stimulating Factor Market Size (000 Units) and Y-o-Y Growth
4.5.3. Granulocyte-Colony Stimulating Factor Market Absolute $ Opportunity
5. Global Granulocyte-Colony Stimulating Factor Market Analysis and Forecast by Type
5.1. Market Trends
5.2. Introduction
5.2.1. Basis Point Share (BPS) Analysis by Type
5.2.2. Y-o-Y Growth Projections by Type
5.3. Granulocyte-Colony Stimulating Factor Market Size and Volume Forecast by Type
5.3.1. Capsules
5.3.2. Tablets
5.3.3. Others
5.4. Absolute $ Opportunity Assessment by Type
5.5. Market Attractiveness/Growth Potential Analysis by Type
6. Global Granulocyte-Colony Stimulating Factor Market Analysis and Forecast by Application
6.1. Market Trends
6.2. Introduction
6.2.1. Basis Point Share (BPS) Analysis by Application
6.2.2. Y-o-Y Growth Projections by Application
6.3. Granulocyte-Colony Stimulating Factor Market Size and Volume Forecast by Application
6.3.1. Oncological Diseases
6.3.2. Blood Disorders
6.3.3. Growth Hormone Deficiencies
6.3.4. Chronic and Autoimmune Disorders
6.3.5. Others
6.4. Absolute $ Opportunity Assessment by Application
6.5. Market Attractiveness/Growth Potential Analysis by Application
7. Global Granulocyte-Colony Stimulating Factor Market Analysis and Forecast by Sales Channel
7.1. Market Trends
7.2. Introduction
7.2.1. Basis Point Share (BPS) Analysis by Sales Channel
7.2.2. Y-o-Y Growth Projections by Sales Channel
7.3. Granulocyte-Colony Stimulating Factor Market Size and Volume Forecast by Sales Channel
7.3.1. Manufacturer/Distributor/Service Provider
7.3.2. Aftermarket
7.4. Absolute $ Opportunity Assessment by Sales Channel
7.5. Market Attractiveness/Growth Potential Analysis by Sales Channel
8. Global Granulocyte-Colony Stimulating Factor Market Analysis and Forecast by Region
8.1. Market Trends
8.2. Introduction
8.2.1. Basis Point Share (BPS) Analysis by Region
8.2.2. Y-o-Y Growth Projections by Region
8.3. Granulocyte-Colony Stimulating Factor Market Size and Volume Forecast by Region
8.3.1. North America
8.3.2. Latin America
8.3.3. Europe
8.3.4. Asia Pacific
8.3.5. Middle East and Africa (MEA)
8.4. Absolute $ Opportunity Assessment by Region
8.5. Market Attractiveness/Growth Potential Analysis by Region
8.6. Global Granulocyte-Colony Stimulating Factor Demand Share Forecast, 2019-2026
9. North America Granulocyte-Colony Stimulating Factor Market Analysis and Forecast
9.1. Introduction
9.1.1. Basis Point Share (BPS) Analysis by Country
9.1.2. Y-o-Y Growth Projections by Country
9.2. North America Granulocyte-Colony Stimulating Factor Market Size and Volume Forecast by Country
9.2.1. U.S.
9.2.2. Canada
9.3. Absolute $ Opportunity Assessment by Country
9.4. North America Granulocyte-Colony Stimulating Factor Market Size and Volume Forecast by Application
9.4.1. Oncological Diseases
9.4.2. Blood Disorders
9.4.3. Growth Hormone Deficiencies
9.4.4. Chronic and Autoimmune Disorders
9.4.5. Others
9.5. Basis Point Share (BPS) Analysis by Application
9.6. Y-o-Y Growth Projections by Application
9.7. North America Granulocyte-Colony Stimulating Factor Market Size and Volume Forecast by Type
9.7.1. Capsules
9.7.2. Tablets
9.7.3. Others
9.8. Basis Point Share (BPS) Analysis by Type
9.9. Y-o-Y Growth Projections by Type
9.10. Market Attractiveness/Growth Potential Analysis
9.10.1. By Country
9.10.2. By Product Type
9.10.3. By Application
9.10.4. By Sales Channel
9.11. North America Granulocyte-Colony Stimulating Factor Demand Share Forecast, 2019-2026
10. Latin America Granulocyte-Colony Stimulating Factor Market Analysis and Forecast
10.1. Introduction
10.1.1. Basis Point Share (BPS) Analysis by Country
10.1.2. Y-o-Y Growth Projections by Country
10.1.3. Latin America Average Pricing Analysis
10.2. Latin America Granulocyte-Colony Stimulating Factor Market Size and Volume Forecast by Country
10.2.1. Brazil
10.2.2. Mexico
10.2.3. Rest of Latin America
10.3. Absolute $ Opportunity Assessment by Country
10.4. Latin America Granulocyte-Colony Stimulating Factor Market Size and Volume Forecast by Application
10.4.1. Oncological Diseases
10.4.2. Blood Disorders
10.4.3. Growth Hormone Deficiencies
10.4.4. Chronic and Autoimmune Disorders
10.4.5. Others
10.5. Basis Point Share (BPS) Analysis by Application
10.6. Y-o-Y Growth Projections by Application
10.7. Latin America Granulocyte-Colony Stimulating Factor Market Size and Volume Forecast by Type
10.7.1. Capsules
10.7.2. Tablets
10.7.3. Others
10.8. Basis Point Share (BPS) Analysis by Type
10.9. Y-o-Y Growth Projections by Type
10.10. Market Attractiveness/Growth Potential Analysis
10.10.1. By Country
10.10.2. By Product Type
10.10.3. By Application
10.10.4. By Sales Channel
10.11. Latin America Granulocyte-Colony Stimulating Factor Demand Share Forecast, 2019-2026
11. Europe Granulocyte-Colony Stimulating Factor Market Analysis and Forecast
11.1. Introduction
11.1.1. Basis Point Share (BPS) Analysis by Country
11.1.2. Y-o-Y Growth Projections by Country
11.1.3. Europe Average Pricing Analysis
11.2. Europe Granulocyte-Colony Stimulating Factor Market Size and Volume Forecast by Country
11.2.1. Germany
11.2.2. France
11.2.3. Italy
11.2.4. U.K.
11.2.5. Spain
11.2.6. Russia
11.2.7. Rest of Europe
11.3. Absolute $ Opportunity Assessment by Country
11.4. Europe Granulocyte-Colony Stimulating Factor Market Size and Volume Forecast by Application
11.4.1. Oncological Diseases
11.4.2. Blood Disorders
11.4.3. Growth Hormone Deficiencies
11.4.4. Chronic and Autoimmune Disorders
11.4.5. Others
11.5. Basis Point Share (BPS) Analysis by Application
11.6. Y-o-Y Growth Projections by Application
11.7. Europe Granulocyte-Colony Stimulting Factor Market Size and Volume Forecast by Type
11.7.1. Capsules
11.7.2. Tablets
11.7.3. Others
11.8. Basis Point Share (BPS) Analysis by Type
11.9. Y-o-Y Growth Projections by Type
11.10. Market Attractiveness/Growth Potential Analysis
11.10.1. By Country
11.10.2. By Product Type
11.10.3. By Application
11.10.4. By Sales Channel
11.11. Europe Granulocyte-Colony Stimulating Factor Demand Share, 2019-2026
12. Asia Pacific Granulocyte-Colony Stimulating Factor Market Analysis and Forecast
12.1. Introduction
12.1.1. Basis Point Share (BPS) Analysis by Country
12.1.2. Y-o-Y Growth Projections by Country
12.1.3. Asia Pacific Average Pricing Analysis
12.2. Asia Pacific Granulocyte-Colony Stimulating Factor Market Size and Volume Forecast by Country
12.2.1. China
12.2.2. Japan
12.2.3. South Korea
12.2.4. India
12.2.5. Australia
12.2.6. Rest of Asia Pacific (APAC)
12.3. Absolute $ Opportunity Assessment by Country
12.4. Asia Pacific Granulocyte-Colony Stimulating Factor Market Size and Volume Forecast by Application
12.4.1. Oncological Diseases
12.4.2. Blood Disorders
12.4.3. Growth Hormone Deficiencies
12.4.4. Chronic and Autoimmune Disorders
12.4.5. Others
12.5. Basis Point Share (BPS) Analysis by Application
12.6. Y-o-Y Growth Projections by Application
12.7. Asia Pacific Granulocyte-Colony Stimulating Factor Market Size and Volume Forecast by Type
12.7.1. Capsules
12.7.2. Tablets
12.7.3. Others
12.8. Basis Point Share (BPS) Analysis by Type
12.9. Y-o-Y Growth Projections by Type
12.10. Market Attractiveness/Growth Potential Analysis
12.10.1. By Country
12.10.2. By Product Type
12.10.3. By Application
12.10.4. By Sales Channel
12.11. Asia Pacific Granulocyte-Colony Stimulating Factor Demand Share, 2019-2026
13. Middle East & Africa Granulocyte-Colony Stimulating Factor Market Analysis and Forecast
13.1. Introduction
13.1.1. Basis Point Share (BPS) Analysis by Country
13.1.2. Y-o-Y Growth Projections by Country
13.1.3. Asia Pacific Average Pricing Analysis
13.2. Middle East & Africa Granulocyte-Colony Stimulating Factor Market Size and Volume Forecast by Country
13.2.1. Saudi Arabia
13.2.2. South Africa
13.2.3. UAE
13.2.4. Rest of Middle East & Africa (MEA)
13.3. Absolute $ Opportunity Assessment by Country
13.4. Middle East & Africa Granulocyte-Colony Stimulating Factor Market Size and Volume Forecast by Application
13.4.1. Oncological Diseases
13.4.2. Blood Disorders
13.4.3. Growth Hormone Deficiencies
13.4.4. Chronic and Autoimmune Disorders
13.4.5. Others
13.5. Basis Point Share (BPS) Analysis by Application
13.6. Y-o-Y Growth Projections by Application
13.7. Middle East & Africa Granulocyte-Colony Stimulating Factor Market Size and Volume Forecast by Type
13.7.1. Capsules
13.7.2. Tablets
13.7.3. Others
13.8. Basis Point Share (BPS) Analysis by Type
13.9. Y-o-Y Growth Projections by Type
13.10. Market Attractiveness/Growth Potential Analysis
13.10.1. By Country
13.10.2. By Product Type
13.10.3. By Application
13.10.4. By Sales Channel
13.11. Middle East & Africa Granulocyte-Colony Stimulating Factor Demand Share, 2019-2026
14. Competition Landscape
14.1. Global Granulocyte-Colony Stimulating Factor Market: Market Share Analysis
14.2. Granulocyte-Colony Stimulating Factor Distributors and Customers
14.3. Granulocyte-Colony Stimulating Factor Market: Competitive Dashboard
14.4. Company Profiles (Details Overview, Financials, Developments, Strategy)
14.4.1. BioCad
14.4.1.1. Overview
14.4.1.2. Financials
14.4.1.3. Developments
14.4.1.4. Strategic Outlook
14.4.2. Dong-A Socio Group
14.4.2.1. Overview
14.4.2.2. Financials
14.4.2.3. Developments
14.4.2.4. Strategic Outlook
14.4.3. Pfizer
14.4.3.1. Overview
14.4.3.2. Financials
14.4.3.3. Developments
14.4.3.4. Strategic Outlook
14.4.4. Intas Pharmaceuticals
14.4.4.1. Overview
14.4.4.2. Financials
14.4.4.3. Developments
14.4.4.4. Strategic Outlook
14.4.5. Novartis AG
14.4.5.1. Overview
14.4.5.2. Financials
14.4.5.3. Developments
14.4.5.4. Strategic Outlook
14.4.6. Stada Arzneimittel
14.4.6.1. Overview
14.4.6.2. Financials
14.4.6.3. Developments
14.4.6.4. Strategic Outlook
14.4.7. Teva Pharmaceutical Industries
14.4.7.1. Overview
14.4.7.2. Financials
14.4.7.3. Developments
14.4.7.4. Strategic Outlook
14.4.8. Amgen
14.4.8.1. Overview
14.4.8.2. Financials
14.4.8.3. Developments
14.4.8.4. Strategic Outlook
14.4.9. Dr. Reddy's Laboratories
14.4.9.1. Overview
14.4.9.2. Financials
14.4.9.3. Developments
14.4.9.4. Strategic Outlook
14.4.10. COMPANY 10
14.4.10.1. Overview
14.4.10.2. Financials
14.4.10.3. Developments
14.4.10.4. Strategic Outlook
14.4.11. COMPANY 11
14.4.11.1. Overview
14.4.11.2. Financials
14.4.11.3. Developments
14.4.11.4. Strategic Outlook
14.4.12. COMPANY 12
14.4.12.1. Overview
14.4.12.2. Financials
14.4.12.3. Developments
14.4.12.4. Strategic Outlook
14.4.13. COMPANY 13
14.4.13.1. Overview
14.4.13.2. Financials
14.4.13.3. Developments
14.4.13.4. Strategic Outlook
14.4.14. COMPANY 14
14.4.14.1. Overview
14.4.14.2. Financials
14.4.14.3. Developments
14.4.14.4. Strategic Outlook
14.4.15. COMPANY 15
14.4.15.1. Overview
14.4.15.2. Financials
14.4.15.3. Developments
14.4.15.4. Strategic Outlook
14.4.16. COMPANY 16
14.4.16.1. Overview
14.4.16.2. Financials
14.4.16.3. Developments
14.4.16.4. Strategic Outlook
14.4.17. COMPANY 17
14.4.17.1. Overview
14.4.17.2. Financials
14.4.17.3. Developments
14.4.17.4. Strategic Outlook
14.4.18. COMPANY 18
14.4.18.1. Overview
14.4.18.2. Financials
14.4.18.3. Developments
14.4.18.4. Strategic Outlook
14.4.19. COMPANY 19
14.4.19.1. Overview
14.4.19.2. Financials
14.4.19.3. Developments
14.4.19.4. Strategic Outlook
14.4.20. COMPANY 20
14.4.20.1. Overview
14.4.20.2. Financials
14.4.20.3. Developments
14.4.20.4. Strategic Outlook